A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Precambrian bodies === The Earth formed around 4.6 billion years ago, with unicellular life emerging somewhat later after the cessation of the Late Heavy Bombardment, a period of intense asteroid impacts possibly caused by migration of the gas giant planets to their current orbits, however multicellularity and bodies are a relatively recent event in Earth's history. Bodies first started appearing towards the end of the Precambrian Era, during the Ediacaran period. The fossils of the Ediacaran period were first found in Southern Australia in the Ediacara Hills, hence the name. However these fossils were initially thought to be part of the Cambrian and it wasn't until the late 1950s when Martin Glaessner identified the fossils as actually being from the Precambrian era. The fossils that were found date to about 600 million years ago and are found in a variety of morphologies.
=== Hard nanoparticles === For hard particles, Pauling's rules are useful in understanding the structure of ionic compounds in the early days, and the later entropy maximization principle shows favor of dense packing in the system. Therefore, finding the densest packing for a given shape is a starting point for predicting the structure of hard nanoparticle superlattices. For spherical particles, the densest packings are face-centered cubic and hexagonal close-packed from the Kepler–Hales theorem. Different particle shapes / polyhedra create diverse complex packing structures in order to minimize the entropy of the system. By computer simulations, four structure categories are classified for faceted polyhedra nanoparticles according to their long-range order and short-range order, which are liquid crystals, plastic crystals, crystals, and disordered structures.
=== Cleavage products === LL-37 is cleaved into a number of smaller fragments which retain anti-microbial and anti-cancer effects but generally have a lower toxicity to human cells. RK-31, KS-30 and KR-20 are naturally occurring fragments, while other related peptides have been made synthetically based on natural fragments of LL-37 during research into cathelicidins, and in some cases have amino acid substitutions.
Sources: en.wikipedia.org
Urinalysis is essential in chronic kidney disease in cats. Damage to as little as two thirds of the nephrons results in a reduced ability to concentrate urine and the specific weight falls below 1030 N-m−3. Protein loss via the kidney is detected by an increase in the protein/creatinine ratio in the urine (UPC), as 24-hour collection samples are impractical in cats. The UPC is a good marker for the early detection of CNE, as it reveals renal dysfunction even before the creatinine in the blood rises. The urine sediment can also show effusions from the renal tubules (cylinder), and in chronic bacterial renal pelvic inflammation bacteria or pus can also be detected. The detection of small amounts of albumin (< 300 mg/l, "microalbuminuria") is very sensitive, but not very specific for chronic kidney disease.
The side corridors are structurally highly sophisticated and remain visible to this day. A low platform runs along the external wall of each corridor, on which rows of statues were displayed, with murals behind them including the figure of the painter in tunic and boots. Above them, the top of each corridor formed a high vault, equipped with a lunette on the southern side, and decorated over its length with rows of devatas behind a balustrade, standing around a Buddha Maitreya, and on top of them landscapes with rhombus losange designs with monks, animals, trees and ponds, of the type seen in vault of the Cave of the Hippocampi (Cave 118).
The suit contains an on-board computer system that constantly monitors the user's health and vital signs, and reacts to any changes in the user's condition. It also projects a heads-up display (HUD) which displays Gordon's health and suit charge level, remaining ammunition, and a crosshair. As a means of immersing the player in the role, Gordon never speaks, and there are no cutscenes or mission briefings—all action is viewed through Gordon's eyes, with the player retaining control of Gordon's actions at nearly all times. Gordon does not appear to wear the helmet, although other dead scientists that appear throughout the game have one. The images of Gordon are only seen on the game's cover and menu pages, and also in advertisements, making them marketing tools rather than pictures of what Gordon is "really like". Gabe Newell has stated that Valve sees no reason to give Gordon a voice. In Half-Life, Gordon wears the Mark IV suit. Later in the game, the suit is equipped with an optional long-jump module so Gordon can leap great distances. It is charged using power modules throughout Black Mesa. In Half-Life 2 Gordon receives the upgraded Mark V suit, which lacks the long-jump module but gains several new abilities. It features a visual zooming capability, limited sprinting, an anti-venom injector, an optional ammo and a health counter on the crosshair, and has been modified to use Combine power nodes to charge the suit.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.